<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888628</url>
  </required_header>
  <id_info>
    <org_study_id>IAK</org_study_id>
    <nct_id>NCT00888628</nct_id>
  </id_info>
  <brief_title>Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients</brief_title>
  <official_title>Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Area Diabetes Endocrinology Research Center (funded by NIDDK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to learn if islet transplantation is an effective treatment for
      Type 1 diabetes in people who have had a kidney transplant.

      The primary objectives of the study are:

      - To set up islet transplantation in patients who have had a kidney transplant and who are
      using an immunosuppressive regimen that works

      The Secondary objective of the study is:

        -  To find out if successful islet transplantation leads to improved metabolic control and
           reduced renal complication from diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving
      insulin independence. For the first islet transplant, patients will receive induction therapy
      with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance
      immunosuppression regimen already in place for their renal allograft. Induction therapy for
      subsequent transplants will be 2doses of basiliximab.

      All patients will receive Etanercept to promote engraftment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Independence With Both an HbA1c â‰¤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease in HbA1c</measure>
    <time_frame>1 year after subject's first islet transplant</time_frame>
    <description>Subjects will have a decrease in HbA1c of at least &gt;1%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable or Decrease in Urinary Albumin and Creatinine Ratio and Serum Creatinine</measure>
    <time_frame>1 year after subjects initial islet transplant</time_frame>
    <description>Proteinuria and serum creatinine will be stable or decreased as compared to pre-transplant values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An Absence Cardiovascular Events, Cerebral Vascular Accident, and Myocardial Infarction</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on Vision</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
    <description>Improvement of frequency of interventions and from changes in reported visual acuity with optical refraction and severity of diabetic retinopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Negative Renal Impact Measures</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
    <description>Loss of allograft survivial (return to dialysis, retransplant, death) and Renal allograft function meausred by SCr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Metabolic Control</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
    <description>Whether there is an improvement in metabolic control in IAK will be evaluated based on improvement in
basal c-peptide levels,
MMTT,
insulin requirements, and
c-peptide to glucose, creatinine ratio (CPGCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease of Severe Hypoglycemic Events</measure>
    <time_frame>1 year after subject's first transplant</time_frame>
    <description>Subjects will have a decrease in severe hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Insulin Requriements</measure>
    <time_frame>1 year after the subject's first islet transplant</time_frame>
    <description>Evidence of partial success will be considered for subjects who have a reduction in insulin requirements but who are not insulin independent. This will be assessed by comparing the pre-transplant insulin requirement expressed as insulin units per kg per day with the requirement preceding subsequent islet transplants and the insulin requirements at 6 months and 1, 2, and 3 years after the first and last transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Diabetes Mellitus, Type I</condition>
  <arm_group>
    <arm_group_label>Islet transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Purified Pancreatic Islets</intervention_name>
    <description>Islet after kidney transplant in patients with type I diabetes.</description>
    <arm_group_label>Islet transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Given as induction for islet cell transplant</description>
    <arm_group_label>Islet transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects

          -  Age 18 to 70 years of age

          -  Have insulin dependent Diabetes Mellitus Type 1

          -  Are post-renal transplant on maintenance immunosuppression with stable renal function

          -  HbA1c &gt; 7.5% or &lt; 7.5% and hypoglycemia unawareness

        Exclusion Criteria:

          -  Weight more than 90 kg

          -  Insulin requirement &gt; 60 Units/day

          -  Other (non-kidney) organ transplants except prior failed pancreatic graft.

          -  Untreated or unstable proliferative diabetic retinopathy

          -  Presence of de novo antibody production since the renal allograft or either Class I or
             Class II panel-reactive anti-HLA antibodies

          -  Active infection

          -  Negative screen for Epstein-Barr virus (EBV)

          -  Any history of malignancy except for completely resected squamous or basal cell
             carcinoma of the skin

          -  History of Factor V Leiden mutation

          -  Any coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g.
             warfarin) after transplantation (low-dose aspirin treatment is allowed) or subjects
             with international normalized ratio (INR) &gt; 1.5

          -  Severe co-existing cardiac disease

          -  Persistent elevation of liver function tests at the time of study entry

          -  Acute or chronic pancreatitis

          -  Male subjects with elevation of prostate specific antigen

          -  Pregnancy

          -  Positive screen for polyoma (BK) virus

          -  Untreated hyperlipidemia

          -  Recent hemorrhagic stroke

          -  Factors associated with an increased risk of bleeding

        Contact PI for complete Incl-Excl criteria list.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James F Markmann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <results_first_submitted>May 13, 2015</results_first_submitted>
  <results_first_submitted_qc>November 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2017</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>James F. Markmann, MD, PhD</investigator_full_name>
    <investigator_title>Chief Division of Transplantation</investigator_title>
  </responsible_party>
  <keyword>Type I diabetes</keyword>
  <keyword>Islet after Kidney Transplant</keyword>
  <keyword>Islet transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Islet Transplant</title>
          <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Transplanted</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Islet Transplant</title>
          <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Independence With Both an HbA1c â‰¤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.</title>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Independence With Both an HbA1c â‰¤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease in HbA1c</title>
        <description>Subjects will have a decrease in HbA1c of at least &gt;1%</description>
        <time_frame>1 year after subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease in HbA1c</title>
          <description>Subjects will have a decrease in HbA1c of at least &gt;1%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stable or Decrease in Urinary Albumin and Creatinine Ratio and Serum Creatinine</title>
        <description>Proteinuria and serum creatinine will be stable or decreased as compared to pre-transplant values</description>
        <time_frame>1 year after subjects initial islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Stable or Decrease in Urinary Albumin and Creatinine Ratio and Serum Creatinine</title>
          <description>Proteinuria and serum creatinine will be stable or decreased as compared to pre-transplant values</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>An Absence Cardiovascular Events, Cerebral Vascular Accident, and Myocardial Infarction</title>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>An Absence Cardiovascular Events, Cerebral Vascular Accident, and Myocardial Infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact on Vision</title>
        <description>Improvement of frequency of interventions and from changes in reported visual acuity with optical refraction and severity of diabetic retinopathy</description>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Impact on Vision</title>
          <description>Improvement of frequency of interventions and from changes in reported visual acuity with optical refraction and severity of diabetic retinopathy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Negative Renal Impact Measures</title>
        <description>Loss of allograft survivial (return to dialysis, retransplant, death) and Renal allograft function meausred by SCr</description>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Negative Renal Impact Measures</title>
          <description>Loss of allograft survivial (return to dialysis, retransplant, death) and Renal allograft function meausred by SCr</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Metabolic Control</title>
        <description>Whether there is an improvement in metabolic control in IAK will be evaluated based on improvement in
basal c-peptide levels,
MMTT,
insulin requirements, and
c-peptide to glucose, creatinine ratio (CPGCR).</description>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Metabolic Control</title>
          <description>Whether there is an improvement in metabolic control in IAK will be evaluated based on improvement in
basal c-peptide levels,
MMTT,
insulin requirements, and
c-peptide to glucose, creatinine ratio (CPGCR).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease of Severe Hypoglycemic Events</title>
        <description>Subjects will have a decrease in severe hypoglycemic events</description>
        <time_frame>1 year after subject's first transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease of Severe Hypoglycemic Events</title>
          <description>Subjects will have a decrease in severe hypoglycemic events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Insulin Requriements</title>
        <description>Evidence of partial success will be considered for subjects who have a reduction in insulin requirements but who are not insulin independent. This will be assessed by comparing the pre-transplant insulin requirement expressed as insulin units per kg per day with the requirement preceding subsequent islet transplants and the insulin requirements at 6 months and 1, 2, and 3 years after the first and last transplant.</description>
        <time_frame>1 year after the subject's first islet transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplant</title>
            <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Insulin Requriements</title>
          <description>Evidence of partial success will be considered for subjects who have a reduction in insulin requirements but who are not insulin independent. This will be assessed by comparing the pre-transplant insulin requirement expressed as insulin units per kg per day with the requirement preceding subsequent islet transplants and the insulin requirements at 6 months and 1, 2, and 3 years after the first and last transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Islet Transplant</title>
          <description>Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
Induction therapy for subsequent transplants will be 2 doses of basiliximab.
All patients will receive Etanercept to promote engraftment.
Purified Pancreatic Islets: Islet after kidney transplant in patients with type I diabetes.
Etanercept: Given as induction for islet cell transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction (Elevated Temp 104.7)</sub_title>
                <description>Elevated temp during Thymoglobulin infusion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <description>Soft tissue infection of foot. This is an exacerbation of a pre-existing condition</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertenstion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Recurrent UTIs at baseline</description>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <description>Elevated Creatinine, resolved.</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James F. Markmann, M.D. Ph.D - Chief, Division of Transplant Surgery</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-643-4087</phone>
      <email>kcrisalli@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

